Start: 08 Nov 2021, 16:00
End: 08 Nov 2021, 17:00
Speaker: Professor Carl Goodyear, University of Glasgow, UK
Speaker: Dr Sheeba Irshad, King's College London, UK
Speaker: Ms Rachel Kahn, Blood Cancer UK, UK
Speaker: Dr Stephen Lockhart, Pfizer, UK
This session will cover the evidence of SARS COV-2 vaccine effectiveness in the cancer patient population, focusing particularly on solid and haematological tumours as the latter group seem to pose a higher risk. As a comparison, speakers will discuss their current knowledge of the effectiveness of existing vaccines in this population and consider the effectiveness in relation to different tumour types, the factors influencing vaccine responses, as well as strategies around vaccine development.